Drug Trial Radar · NCT00620451
Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease
Last checked: Nov 19, 2026Latest source record: Sep 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Feb 2008
Primary completion
Jul 2009
Study completion Dec 2009
Sponsor
- Lead sponsor
- 9 Meters Biopharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 21, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was conducted to assess the safety and efficacy of larazotide acetate versus placebo in inducing remission in subjects with active celiac disease.
Conditions
- Celiac Disease
Interventions
larazotide acetateDrug
gelatin capsule
placeboDrug
gelatin capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the efficacy of larazotide acetate in inducing remission in subjects with active celiac diseaseTime frame: duodeno-jejunal biopsies were performed at Baseline and Day 56
Locations
33 sites in 3 countries. Site status is shown where the registry gives one.
Study Site
Orange, California
Study Site
San Francisco, California
Study Site
Torrington, Connecticut
Study Site
Jacksonville, Florida
Study Site
Topeka, Kansas
Study Site
Lexington, Kentucky
Study Site
Hagerstown, Maryland
Study Site
Silver Spring, Maryland
Study Site
Chesterfield, Michigan
Study Site
Troy, Michigan
Study Site
Rochester, Minnesota
Study Site
Asheville, North Carolina
Study Site
Harrisburg, North Carolina
Study Site
Gallipolis, Ohio
Study Site
Paoli, Pennsylvania
Study Site
Philadelphia, Pennsylvania
Study Site
Pittsburgh, Pennsylvania
Study Site
Sioux Falls, South Dakota
Study Site
Franklin, Tennessee
Study Site
Houston, Texas
Study Site
Edmonton, Alberta, Canada
Study Site
Abbotsford British Columbia, British Columbia, Canada
Study Site
Kelowna, British Columbia, Canada
Study Site
Richmond Hill, Ontario, Canada
Study Site
Barcelona, Spain
Study Site
Huesca, Spain
Study Site
León, Spain
Study Site
Madrid, Spain
Study Site
Madrid, Spain
Study site
Madrid, Spain
Study Site
Reus, Spain
Study Site
Valladolid, Spain
Study Site
Palma, Mallorca, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.